Genprex, Inc. (GNPX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Genprex, Inc. for the period ended March 31, 2026. Genprex is a clinical-stage gene therapy company developing oncology and diabetes treatments. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company. As of May 11, 2026, there were 10,586,402 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,461,895) | $(3,964,601) |
| Net Loss Per Share (Basic & Diluted) | $(0.64) | $(12.98) |
| Operating Expenses | $4,494,184 | $3,969,292 |
| Cash and Cash Equivalents (End of Period) | $18,049,255 | $3,468,338 |
| Net Cash Used in Operating Activities | $(3,138,457) | $(4,161,424) |
| Net Cash Provided by Financing Activities | $13,356,857 | $6,028,102 |
| Total Assets | $20,306,266 | $10,159,010 |
| Total Liabilities | $3,375,996 | $2,197,134 |
| Stockholders' Equity | $16,930,270 | $7,961,876 |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased by approximately $10.2 million, driven primarily by net proceeds of $13.36 million from the sale of 5.7 million shares under the 2023 At-The-Market (ATM) Facility.
- Operating Expenses: Total operating expenses increased by $524,892 (13%) compared to Q1 2025. Research and Development (R&D) expenses rose 8% to $2.75 million, while General and Administrative (G&A) expenses increased 22% to $1.75 million. The G&A increase was partly due to higher corporate franchise tax following a 1-for-50 reverse stock split in October 2025.
- Net Loss: Net loss increased by $497,294 (13%) to $4.46 million. The increase in loss per share was significantly mitigated by the reverse stock split and increased share count, resulting in a reported loss per share of $(0.64) compared to $(12.98) in the prior year.
- Balance Sheet: Total assets more than doubled to $20.3 million, reflecting the cash infusion. Accounts payable increased to $1.66 million from $743,070.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- Acclaim-1 (NSCLC): Enrolling in the Phase 2a expansion portion. Interim analysis of the first 19 patients is expected in the second half of 2026. One patient has maintained partial remission for approximately 48 months.
- Acclaim-3 (SCLC): Enrolling in the Phase 2 expansion portion. Interim analysis of the first 25 patients is expected in the second half of 2026. The trial has received FDA Fast Track and Orphan Drug Designations.
- Diabetes (GPX-002): Met with the FDA in February 2026 regarding IND-enabling preclinical studies. Plans to continue preclinical animal studies and initiate clinical scale production.
- Liquidity and Going Concern: Management estimates current cash resources will fund operations into the second half of 2027. However, the filing explicitly states that recurring losses and the need for additional financing raise substantial doubt about the company's ability to continue as a going concern. No revenue is expected until regulatory approval and commercialization.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses related to a lack of segregation of duties and insufficient depth of in-house accounting personnel. Remediation plans are underway.
- Capital Strategy: The company continues to utilize its 2023 ATM Facility and has an Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC, though no sales were made under the ELOC during the quarter.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's ability to secure additional funding before the second half of 2027, as current cash burn relies on continued equity financing.
- Internal Control Weaknesses: Monitor the remediation of material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties.
- Clinical Milestones: Track the interim analysis results for the Acclaim-1 and Acclaim-3 trials expected in the second half of 2026, which are critical for future valuation and funding.
- Dilution Risk: Note the significant increase in share count (from ~3.3 million to ~9.0 million outstanding) due to the reverse split and recent ATM sales, which impacts per-share metrics.
- Intellectual Property Commitments: Review ongoing royalty and milestone payment obligations to license partners (MD Anderson, University of Pittsburgh, etc.) which could impact future cash flow upon commercialization.